Crizotinib and renal insufficiency: A case report and review of the literature

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 310-313

  Martín Martorell, Paloma ^a   Huerta Alvaro, Marisol ^a   Solís Salguero, Miguel A ^a   Insa Molla, Amelia ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

ALK; Crizotinib; Lung adenocarcinoma; Renal insufficiency; Toxicity; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CREATININE; CRIZOTINIB; FUROSEMIDE; LACTATE DEHYDROGENASE; PACLITAXEL; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG ADENOCARCINOMA; MAINTENANCE THERAPY; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; ADENOCARCINOMA; CHEMICALLY INDUCED; KIDNEY FUNCTION TEST; LUNG NEOPLASMS;

ADENOCARCINOMA; AGED; HUMANS; KIDNEY FUNCTION TESTS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RENAL INSUFFICIENCY;

EID: 84901951935     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.001     Document Type: Article

References (10)

1. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
2. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
3. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase I study. Lancet 2012, 13:1011-1019.
4. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
5. Kelly R.J., Billemont B., Rixe O. Renal toxicity of targeted therapies. Targ Oncol 2009, 4:121-133.
6. Jhaveri K.D., Flombaum C.D., Kroog G., Glezerman I.G. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephrol Clin Pract 2011, 117:c312-c319.
7. Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49:186-193.
8. US Food and Drug Administration Approval History XALKORI, NDA no. 202570. http://labeling.pfizer.com/showlabeling.aspx%3Fid=676.
9. Gastaud L., Ambrosetti D., Otto J., Marquette C.H., Coutts M., Hofman P., et al. Acute kidney injury following crizotinib administration for non-small-cell lung adenocarcinoma. Lung Cancer 2013, 82:362-364. [Epub ahead of print]. 10.1016/j.lungcan.2013.08.007.
10. Brosnan E.M., Weickhardt A.J., Lu X., Maxon D.A., Barón A.E., Chonchol M., et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small-cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 2013, [Epub ahead of print]. 10.1002/cncr.28478.